Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue: +21.8%
EPS: −80.6%
Free cash flow: +6.78%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

44.61 1.28 −2.79%

Follow ALKS

Alert me

Market cap: $7.5B
P/E: 0.0×
Fwd P/E: −85.9×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alkermes plc (ALKS) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
VIVITROL	468	31.70%
ARISTADA and ARISTADA INITIO	370	25.07%
LYBALVI	347	23.49%
Royalty	245	16.62%
Manufacturing Revenue	46	3.12%
Gross margin		86.69%
Operating margin		17.21%
Pre-tax margin		19.75%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
VIVITROL	468 31.70%	457 29.36%	400 24.07%	379 34.13%	344 29.30%	311 29.91%	335 28.64%	303 27.65%	269 29.81%	209 28.03%
ARISTADA and ARISTADA INITIO	370 25.07%	346 22.23%	328 19.70%	302 27.17%	275 23.46%	241 23.20%	189 16.15%	148 13.50%	94 10.35%	47 6.32%
LYBALVI	347 23.49%	280 17.98%	192 11.54%	96 8.64%	8 0.70%	—	—	—	—	—
Royalty	245 16.62%	355 22.77%	601 36.12%	220 19.75%	436 37.16%	365 35.13%	344 29.35%	394 35.97%	352 39.02%	—
Manufacturing Revenue	46 3.12%	119 7.67%	142 8.57%	112 10.11%	106 9.00%	119 11.46%	104 8.90%	133 12.16%	153 16.92%	—
Research and development revenue	—	0 0.00%	0 0.00%	0 0.02%	1 0.09%	2 0.19%	53 4.51%	69 6.30%	7 0.80%	2 0.31%
License revenue	—	—	—	2 0.18%	4 0.30%	1 0.10%	146 12.45%	48 4.42%	28 3.10%	—
Manufacturing and royalty revenues	291	474	743	332	542	484	448	527	505	—
Product sales, net	1,185	1,084	920	778	627	552	524	450	363	256
Revenue	1,476	1,558	1,663	1,112	1,174	1,039	1,171	1,094	903	746

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010
U.S.	1,373 93.01%	1,410 90.53%	1,492 89.69%	984 83.85%	839 80.77%	967 82.58%	885 80.84%	700 77.50%	557 74.74%	449 71.40%	398 64.35%	381 66.12%	213 54.58%	77 41.10%	82 45.81%
Rest of world	102 6.94%	146 9.38%	170 10.24%	187 15.96%	197 18.92%	201 17.15%	205 18.71%	194 21.43%	184 24.67%	176 27.98%	213 34.41%	181 31.37%	164 42.16%	109 58.47%	96 53.63%
Ireland	1 0.05%	1 0.08%	1 0.07%	2 0.19%	3 0.31%	3 0.27%	5 0.45%	10 1.07%	4 0.59%	4 0.62%	8 1.24%	14 2.51%	13 3.26%	1 0.43%	1 0.56%
Other, not broken out	—	—	—	—	—	—	—	—	—	—	—	21 3.61%	—	—	—
Revenue	1,476	1,558	1,663	1,174	1,039	1,171	1,094	903	746	628	619	576	390	187	178

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
LYBALVI total prescriptions growth	Q3 FY2026	18.0%	25.0%	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024
LYBALVI total prescriptions growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.